The HER2-HER3 signaling pair is an oncogenic unit in many HER2-driven breast cancers [4], [5], [6] and upregulation of the HER3 receptor has been shown to play a role in resistance to several currently approved drugs [7], [8], [9]. This evidence concerns the gene ERBB2 and breast carcinoma.